Overview
The purpose of this study is to assess the impact of suvorexant on established measures of smoking relapse risk (craving,withdrawal, stress reactivity, latency to self-administration) and to validate the somnolent effect of suvorexant on sleep metrics in a sample of individuals with tobacco use disorder
Eligibility
Inclusion Criteria:
- non-treatment seeking cigarette smokers that report smoking atleast 10 cigarettes per day
Exclusion Criteria:
- greater than mild substance use disorder on drugs other than nicotine
- a Diagnostic and Statistical Manual of Mental Disorders(DSM)-IV axis I psychiatric disorder or neurological disease or disorder requiring ongoing treatment and/or making study participation unsafe
- significant current suicidal or homicidal ideation - medical conditions contraindicating administration of suvorexant (e.g., severe pulmonary disease, severe cardiovascular disease or clinically abnormal EEG, severe liver or kidney disease, seizure disorder, or sleep disorder - particularly narcolepsy)
- taking medications known to have significant drug interactions with the study medication(s) (e.g., Monoamine oxidase inhibitors(MAO) inhibitors, anticonvulsants, haloperidol, phenothiazines, anesthetics, and all sedatives)
- currently or recently (last 3 months) treated for substance use [other than nicotine] or another psychiatric condition
- conditions of probation or parole requiring reports of drug use to officers of the court
- impending incarceration
- pregnant or nursing for female patients
- inability to read, write, or speak English [required for lab tasks and psychometric scales]
- unwillingness to sign a written informed consent form
- subjects with alcohol use disorders or report recent problem drinking (5/4 drinks for males/females in < 2.5 hours or > 10 alcoholic drinks per week)
- any illness,condition, or use of medications which in the opinion of the PI and/or admitting physician would preclude safe and/or successful completion of the study.
